FERNANDO
LÓPEZ-RÍOS MORENO
Profesor asociado de Ciencias de la Salud
Hospital Universitario Marqués de Valdecilla
Santander, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (17)
2024
-
Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach
Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326
-
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
Clinical Cancer Research, Vol. 30, Núm. 14, pp. 3036-3049
2020
-
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Revista Espanola de Patologia, Vol. 53, Núm. 3, pp. 167-181
-
Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 22, Núm. 7, pp. 989-1003
2019
-
Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study
Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2120-2132
2018
-
Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab
Oncologist, Vol. 23, Núm. 9, pp. 1092-1102
2017
-
Biomarkers in pancreatic ductal adenocarcinoma
Clinical and Translational Oncology, Vol. 19, Núm. 12, pp. 1430-1437
-
Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain
Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 667-681
2015
2014
-
A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond
Cancer Letters, Vol. 351, Núm. 1, pp. 30-40
-
Accurate identification of ALK positive lung carcinoma patients: Novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry
PLoS ONE, Vol. 9, Núm. 9
-
Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 103-112
2013
-
Level of HER2 gene amplification predicts response and overall survival in her2-positive advanced gastric cancer treated with trastuzumab
Journal of Clinical Oncology, Vol. 31, Núm. 35, pp. 4445-4452
2012
-
Guidelines for biomarker testing in advanced non-small-cell lung cancer. A National Consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP)
Clinical and Translational Oncology, Vol. 14, Núm. 5, pp. 338-349
-
Recomendaciones para la determinación de biomarcadores en el carcinoma de pulmón no microcítico avanzado. Consenso nacional de la Sociedad Española de Anatomía Patológica y de la Sociedad Española de Oncología Médica
Revista Espanola de Patologia
2011
-
Consenso de la Sociedad Española de Anatomía Patológica (SEAP) y de la Sociedad Española de Oncología Médica (SEOM) sobre la determinación de HER2 en el carcinoma gástrico
Revista Espanola de Patologia, Vol. 44, Núm. 1, pp. 32-48
-
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma
Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 636-651